Mode
Text Size
Log in / Sign up
Phase 2 N=110 Randomized Triple-blind Treatment

Metoclopramide Versus Placebo for GJ Placement

Radiation Exposure · Enteral Nutrition

Enrolled (actual)
110
Serious AEs
0.0%
Results posted
Jul 2020
Primary outcome: Primary: Time to Duodenal Intubation — 1.6; 4.1 Minutes

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Metoclopramide 5 MG/ML Injectable Solution (Drug); Saline (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Duke University
Primary completion
Oct 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to Duodenal Intubation
1.6; 4.1
SECONDARY
Total Procedure Fluoroscopy Time
5.8; 8.8
SECONDARY
Total Procedure Air Kerma
91; 130
SECONDARY
Total Procedure Time
16.4; 19.9

Summary

The goal of this study is to determine whether use of promotility agents to stimulate gastric peristalsis can reduce fluoroscopy time and procedure time during gastrojejunostomy (GJ) tubes placement in interventional radiology (IR). The investigators hypothesize that increased gastric peristalsis will aid in advancing a guidewire through the pylorus, a time consuming and tedious step required during GJ tube placement. In order to maximize scientific rigor and clinical practice impact, the investigators aim to answer this question through a blinded, randomized, placebo controlled trial. Specific Aim 1: To test the hypothesis that a single dose of IV metoclopramide immediately prior to GJ tube placement reduces the fluoroscopy time required to advance a guidewire through the pylorus. Specific Aim 2: To determine whether a single dose of IV metoclopramide immediately prior to GJ tube placement reduces total procedure fluoroscopy time, air kerma and total procedure time. Specific Aim 3: To assess the safety of a single dose of promotility agent prior to GJ tube placement by assessing rates of adverse events in the periprocedural period in patients receiving IV metoclopramide versus placebo.

Eligibility Criteria

Inclusion Criteria

  • 18 years old or older
  • undergoing de novo GJ placement as part of their routine clinical care

Exclusion Criteria

  • Patient pregnant
  • Contraindications to metoclopramide including:
  • allergic reaction
  • pheochromocytoma
  • QTc prolongation
  • history of seizure disorder
  • extrapyramidal symptoms
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03331965). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search